Dual Carfilzomib and Doxorubicin–Loaded Liposomal Nanoparticles for Synergistic Efficacy in Multiple Myeloma
- 1 July 2016
- journal article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 15 (7), 1452-1459
- https://doi.org/10.1158/1535-7163.mct-15-0867
Abstract
Here, we report the synthesis and evaluation of dual drug–loaded nanoparticles as an effective means to deliver carfilzomib and doxorubicin to multiple myeloma tumor cells at their optimal synergistic ratio. First, various molar ratios of carfilzomib to doxorubicin were screened against multiple myeloma cell lines to determine the molar ratio that elicited the greatest synergy using the Chou–Talalay method. The therapeutic agents were then incorporated into liposomes at the optimal synergistic ratio of 1:1 to yield dual drug–loaded nanoparticles with a narrow size range of 115 nm and high reproducibility. Our results demonstrated that the dual drug–loaded liposomes exhibited synergy in vitro and were more efficacious in inhibiting tumor growth in vivo than a combination of free drugs, while at the same time reducing systemic toxicity. Taken together, this study presents the synthesis and preclinical evaluation of dual drug–loaded liposomes containing carfilzomib and doxorubicin for enhanced therapeutic efficacy to improve patient outcome in multiple myeloma. Mol Cancer Ther; 15(7); 1452–9. ©2016 AACR.Keywords
Other Versions
Funding Information
- Leukemia Research Foundation (#W81XWH-15-1-0177)
This publication has 33 references indexed in Scilit:
- Rationally engineered nanoparticles target multiple myeloma cells, overcome cell-adhesion-mediated drug resistance, and show enhanced efficacy in vivoBlood Cancer Journal, 2012
- Nanoparticle-based combination therapy toward overcoming drug resistance in cancerBiochemical Pharmacology, 2012
- Clinical development of liposome based drugs: formulation, characterization, and therapeutic efficacyInternational Journal of Nanomedicine, 2011
- Combinatorial Drug Conjugation Enables Nanoparticle Dual‐Drug DeliverySmall, 2010
- Antitumor Activity of PR-171, a Novel Irreversible Inhibitor of the ProteasomeCancer Research, 2007
- Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination StudiesPharmacological Reviews, 2006
- Prognostic value of bone marrow angiogenesis in multiple myeloma: Use of light microscopy as well as computerized image analyzer in the assessment of microvessel density and total vascular area in multiple myeloma and its correlation with various clinical, histological, and laboratory parametersAmerican Journal of Hematology, 2006
- Determination of Doxorubicin Levels in Whole Tumor and Tumor Nuclei in Murine Breast Cancer TumorsClinical Cancer Research, 2005
- PAD combination therapy (PS‐341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myelomaBritish Journal of Haematology, 2005
- The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applicationsBlood, 2003